Namwiwat Medical Corporation PCL (BKK: NAM)
Thailand
· Delayed Price · Currency is THB 4.620
+0.060 (1.32%)
Nov 22, 2024, 10:00 AM ICT
NAM Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Operating Revenue | 933.29 | 1,101 | 1,099 | 995.36 | 676.61 |
| Other Revenue | 3.82 | 2.32 | 0.99 | - | 2.22 |
| Revenue | 937.11 | 1,103 | 1,100 | 995.36 | 678.84 |
| Revenue Growth (YoY) | -14.84% | 0.25% | 10.55% | 46.63% | - |
| Cost of Revenue | 516.95 | 620.7 | 772.91 | 654.73 | 467.39 |
| Gross Profit | 420.16 | 482.38 | 327.45 | 340.63 | 211.45 |
| Selling, General & Admin | 225.69 | 230.16 | 103.39 | 115.18 | 65.31 |
| Operating Expenses | 225.69 | 230.16 | 103.39 | 115.18 | 65.31 |
| Operating Income | 194.47 | 252.22 | 224.06 | 225.45 | 146.14 |
| Interest Expense | -14.34 | -15.73 | -12.99 | -14.03 | -12.46 |
| Interest & Investment Income | 9.08 | 1.57 | 1.06 | 0.02 | 0.02 |
| Earnings From Equity Investments | - | - | -0.55 | -0.27 | -11.4 |
| Currency Exchange Gain (Loss) | - | - | 13.04 | 1.14 | - |
| Other Non Operating Income (Expenses) | 1.65 | 1.65 | -8.14 | - | - |
| EBT Excluding Unusual Items | 190.86 | 239.71 | 216.48 | 212.3 | 122.3 |
| Gain (Loss) on Sale of Investments | - | - | - | - | 10.65 |
| Gain (Loss) on Sale of Assets | 10.57 | 10.57 | 5.44 | 1.48 | - |
| Pretax Income | 201.44 | 250.28 | 221.91 | 213.78 | 132.95 |
| Income Tax Expense | 39.44 | 49.53 | 46.2 | 44.1 | 22.51 |
| Earnings From Continuing Operations | 161.99 | 200.75 | 175.71 | 169.68 | 110.44 |
| Minority Interest in Earnings | 0.01 | - | - | 4.97 | 1.39 |
| Net Income | 162 | 200.75 | 175.71 | 174.65 | 111.83 |
| Net Income to Common | 162 | 200.75 | 175.71 | 174.65 | 111.83 |
| Net Income Growth | -7.80% | 14.25% | 0.61% | 56.18% | - |
| Shares Outstanding (Basic) | 667 | 615 | 26 | 20 | 20 |
| Shares Outstanding (Diluted) | 667 | 615 | 26 | 20 | 20 |
| Shares Change (YoY) | 2437.32% | 2237.62% | 31.45% | - | - |
| EPS (Basic) | 0.24 | 0.33 | 6.68 | 8.73 | 5.59 |
| EPS (Diluted) | 0.24 | 0.33 | 6.68 | 8.73 | 5.59 |
| EPS Growth | -96.37% | -95.11% | -23.46% | 56.18% | - |
| Free Cash Flow | -87.69 | 228.27 | -81.16 | 93.61 | 104.71 |
| Free Cash Flow Per Share | -0.13 | 0.37 | -3.09 | 4.68 | 5.24 |
| Dividend Per Share | 0.090 | 0.090 | - | - | - |
| Gross Margin | 44.84% | 43.73% | 29.76% | 34.22% | 31.15% |
| Operating Margin | 20.75% | 22.87% | 20.36% | 22.65% | 21.53% |
| Profit Margin | 17.29% | 18.20% | 15.97% | 17.55% | 16.47% |
| Free Cash Flow Margin | -9.36% | 20.69% | -7.38% | 9.40% | 15.42% |
| EBITDA | 217 | 274.5 | 241.25 | 239.88 | - |
| EBITDA Margin | 23.16% | 24.89% | 21.92% | 24.10% | - |
| D&A For EBITDA | 22.54 | 22.28 | 17.19 | 14.43 | - |
| EBIT | 194.47 | 252.22 | 224.06 | 225.45 | 146.14 |
| EBIT Margin | 20.75% | 22.86% | 20.36% | 22.65% | 21.53% |
| Effective Tax Rate | 19.58% | 19.79% | 20.82% | 20.63% | 16.93% |
| Revenue as Reported | 949.33 | 1,115 | 1,111 | 997.98 | 678.84 |
Source: S&P Capital IQ. Standard template. Financial Sources.